Tevogen Bio Announces FDA Clearance of Investigational New Drug (IND) Application For its Cytotoxic T Cell Therapy for COVID-19

Tevogen Bio, a clinical stage biotechnology company, announced that the FDA has cleared its Investigational New Drug application for TVGN-489, Allogeneic COVID-19 Specific Cytotoxic T Lymphocytes, allowing Tevogen Bio to initiate a clinical trial of its investigational COVID-19 treatment.